Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;333:1181-1182 (9 December), doi:10.1136/bmj.39050.672639.80
Early switch from intravenous to oral antibiotics is safe and reduces hospital stay
| The first 150 words of the full text of this article appear below. |
Research into community acquired pneumonia over the past two decades has focused on developing tools to measure the severity of illness and which antibiotics to choose. Several tools can now help clinicians identify patients with severe community acquired pneumonia in clinical settings.1 In people with severe disease, international guidelines recommend early treatment with broad spectrum antibiotics, which provide cover for atypical pathogens.2
It is less clear how best to manage patients during their stay in hospital. In this week's BMJ, a randomised trial by Oosterheert and colleagues reports the effect of switching from intravenous to oral antibiotics after three days rather than seven days in people with severe community acquired pneumonia.3 Until now, the lack of quality trial data in areas such as route of antibiotic administration, duration of treatment, and assessment of clinical stability has led to a conservative approach to management and prolongation of hospital stay.
The
Graham D Mills, infectious diseases physician1, Richard Laing, respiratory physician2
1 Waikato Hospital, Hamilton, New Zealand 3204, 2 Christchurch Hospital, Christchurch, New Zealand 8001
millsg@waikatodhb.govt.nz